Valuation: Syntara Limited

Market Cap 47.09M 33.24M 28.81M 26.97M 24.61M 46.31M 3.17B 316M 124M 1.59B 125M 122M 5.29B P/E 2026 *
-4.8x
P/E 2027 * -4.8x
Enterprise Value 34.19M 24.14M 20.92M 19.58M 17.87M 33.62M 2.3B 230M 89.96M 1.15B 90.62M 88.65M 3.84B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.28%
Yield 2026 *
-
Yield 2027 * -
1 day-11.11%
1 week-14.29%
Current month-5.88%
1 month+4.35%
3 months-11.11%
6 months-31.43%
Current year-31.43%
1 week 0.02
Extreme 0.024
0.04
1 month 0.02
Extreme 0.021
0.04
Current year 0.02
Extreme 0.019
0.04
1 year 0.02
Extreme 0.019
0.04
3 years 0.01
Extreme 0.014
0.1
5 years 0.01
Extreme 0.014
0.15
10 years 0.01
Extreme 0.014
0.37
Manager TitleAgeSince
Chief Executive Officer 64 2013-03-11
Director of Finance/CFO - 2024-08-30
Chief Tech/Sci/R&D Officer - 2022-06-30
Director TitleAgeSince
Director/Board Member 64 2013-03-11
Chairman 68 2023-10-02
Director/Board Member - 2022-12-15
Date Insider Type Main position Quantity % Market Cap.
3/13/25 Buy

Director

9,753,442 0.6008%
9/24/24 Buy

Director

53,571,429 4.1513%
8/12/21 Expiration

Chief Executive Officer

471,000 0.1040%
Change 5-day change 1-year change 3-year change Capi.($)
-11.11%-14.29%-11.11%-52.00% 33.24M
-0.70%+13.34%+75.61%+103.83% 70.51B
-0.16%-0.05%+35.45%+63.68% 54.05B
-1.62%+34.25%+17.43%+491.04% 28.95B
-0.61%+12.51%+54.60%+7.40% 24.05B
0.00%+1.59%-15.06%-13.21% 23.31B
+9.77%+20.16%+260.17%+472.38% 18.67B
-0.44%+5.02%+43.57%-21.62% 18.37B
0.00%+7.46%+30.95%+623.97% 16.1B
-3.08%-8.34%+37.21%+138.52% 12.72B
Average -0.79%+354.29%+52.88%+181.40% 26.68B
Weighted average by Cap. +0.07%+350.10%+57.51%+168.98%

Financials

2026 *2027 *
Net sales - -
Net income -12.35M -8.72M -7.56M -7.07M -6.45M -12.15M -832M -82.94M -32.5M -416M -32.74M -32.03M -1.39B -31.85M -22.49M -19.49M -18.24M -16.65M -31.32M -2.14B -214M -83.81M -1.07B -84.43M -82.59M -3.58B
Net Debt -12.9M -9.11M -7.89M -7.39M -6.74M -12.69M -869M -86.64M -33.94M -435M -34.2M -33.45M -1.45B -32.8M -23.16M -20.07M -18.79M -17.14M -32.26M -2.21B -220M -86.31M -1.11B -86.95M -85.05M -3.69B
Logo Syntara Limited
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Employees
-
Date Price Change Volume
26-08-11 A$0.0240 -11.11% 6,872,135
26-08-10 A$0.0270 -22.86% 6,218,803
26-08-07 A$0.0350 +12.90% 3,404,007
26-08-06 A$0.0310 +6.90% 6,197,165
26-08-05 A$0.0290 +3.57% 2,085,622
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0240AUD
Average target price
0.1050AUD
Spread / Average Target
+337.50%

Quarterly revenue - Rate of surprise